Global Short Bowel Syndrome Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

In this report, the Short Bowel Syndrome Therapeutics Market has been segmented by Drug, Route of Administration, Distribution Channel and Geography.

Short Bowel Syndrome Therapeutics Market, Segmentation by Drug

The Short Bowel Syndrome Therapeutics Market has been segmented by Drug into Glucagon-like Peptide-2 (GLP-2) Analog - Short-acting GLP-2 Analog[Teduglutide (Gattex/Revestive)], - Long-acting GLP-2 Analog[Glepaglutide, Apraglutide (FE 203799) and Others], Glutamine, Growth Hormone, Glucagon-like Peptide-1 (GLP-1) Analog, Insulin (NTRA 9620), TGR5 Agonist, and Others.

Glucagon-like Peptide-2 (GLP-2) Analog - Short-acting GLP-2 Analog [Teduglutide (Gattex/Revestive)]

Short-acting GLP-2 Analog, particularly Teduglutide, dominates the short bowel syndrome therapeutics market, contributing approximately 41% of global revenue in 2022. This GLP-2 analog enhances intestinal absorption and reduces dependence on parenteral nutrition, offering significant clinical benefits for patients with short bowel syndrome.

Glucagon-like Peptide-2 (GLP-2) Analog - Long-acting GLP-2 Analog [Glepaglutide, Apraglutide (FE 203799) and Others]

Long-acting GLP-2 Analogs hold an estimated 29% share of the global short bowel syndrome therapeutics market. These agents offer improved compliance and convenience due to their extended half-life. Ongoing clinical trials and promising results for Glepaglutide and Apraglutide support future growth in this segment.

Glutamine

Glutamine contributes approximately 10% of the global short bowel syndrome therapeutics market. This amino acid supports intestinal mucosal healing and enhances nutrient absorption. Its role as a supportive therapy in combination with other treatments supports steady market demand.

Growth Hormone

Growth Hormone holds an estimated 8% share of the global short bowel syndrome therapeutics market. It enhances intestinal adaptation and reduces parenteral nutrition dependency. The combination of growth hormone with GLP-2 analogs is gaining traction for improving patient outcomes.

Glucagon-like Peptide-1 (GLP-1) Analog

GLP-1 Analogs account for around 4% of the global short bowel syndrome therapeutics market. These agents, though primarily used for diabetes, are being explored for their potential in improving gut motility and nutrient absorption. Ongoing clinical studies support future growth.

Insulin (NTRA 9620)

Insulin (NTRA 9620) holds an estimated 3% share of the global short bowel syndrome therapeutics market. This investigational therapy aims to enhance intestinal growth and function. Its development is supported by promising preclinical and clinical data.

TGR5 Agonist

TGR5 Agonists contribute around 2% of the global short bowel syndrome therapeutics market. These novel agents aim to modulate bile acid signaling pathways to improve intestinal absorption and reduce parenteral nutrition needs. Ongoing research supports potential future applications.

Others

The "Others" category, including emerging therapies and experimental agents, holds an estimated 3% of the global short bowel syndrome therapeutics market. These treatments target unmet needs and offer potential for innovation and future growth.

Short Bowel Syndrome Therapeutics Market, Segmentation by Route of Administration

The Short Bowel Syndrome Therapeutics Market has been segmented by Route of Administration into Injectable and Oral.

Injectable

Injectable therapies dominate the short bowel syndrome therapeutics market, contributing approximately 68% of global revenue in 2022. These include GLP-2 analogs, growth hormone, and insulin-based therapies, which are administered via parenteral routes to ensure targeted delivery and optimal bioavailability. Their proven efficacy and established use drive strong demand in this segment.

Oral

Oral therapies hold an estimated 32% share of the global short bowel syndrome therapeutics market. These include glutamine, GLP-1 analogs, and emerging oral agents targeting intestinal adaptation and nutrient absorption. The convenience of oral administration and growing focus on patient-centric therapies support continued growth in this segment.

Short Bowel Syndrome Therapeutics Market, Segmentation by Distribution Channel

The Short Bowel Syndrome Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

Hospital Pharmacies

Hospital Pharmacies dominate the short bowel syndrome therapeutics market, contributing approximately 52% of global revenue in 2022. These outlets ensure timely access to specialized treatments like injectable GLP-2 analogs and growth hormone therapies. The growing use of advanced therapeutics and rising demand for complex care management support sustained demand.

Retail Pharmacies

Retail Pharmacies account for around 34% of the global short bowel syndrome therapeutics market. These facilities offer a range of oral medications and nutritional supplements for ongoing management. The increasing shift towards outpatient care and growing patient preference for accessible options drive growth in this segment.

Online Pharmacies

Online Pharmacies hold an estimated 14% share of the global short bowel syndrome therapeutics market. The rising trend of digital healthcare platforms and growing demand for home delivery services contribute to this segment’s expansion. Online pharmacies provide convenient access to a wide range of therapeutic products and supportive care options.

Short Bowel Syndrome Therapeutics Market, Segmentation by Geography

In this report, the Short Bowel Syndrome Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Short Bowel Syndrome Therapeutics Market Share (%), by Geographical Region

North America

North America leads the short bowel syndrome therapeutics market, contributing approximately 43% of global revenue in 2022. The region benefits from advanced healthcare infrastructure, strong regulatory frameworks, and the presence of leading market players. The increasing availability of GLP-2 analogs and rising awareness of short bowel syndrome management support robust growth.

Europe

Europe holds around 27% of the global short bowel syndrome therapeutics market. Growth in this region is supported by rising clinical research collaborations, a strong focus on innovative therapies, and increasing access to advanced treatment options. Regulatory initiatives promoting rare disease management further fuel expansion.

Asia Pacific

Asia Pacific accounts for an estimated 20% share of the global short bowel syndrome therapeutics market. Rapidly improving healthcare access, increasing investments in rare disease treatment, and growing diagnostic capabilities contribute to regional growth. Key contributors include China, Japan, and India.

Middle East and Africa

Middle East and Africa contribute approximately 6% of the global short bowel syndrome therapeutics market. Expanding healthcare infrastructure, rising government initiatives to support rare disease treatment, and collaborations with global market leaders enhance growth in this region.

Latin America

Latin America holds around 4% of the global short bowel syndrome therapeutics market. The region's growth is supported by increasing awareness of rare disorders, expanding healthcare access, and improving availability of advanced treatments. Regional initiatives to strengthen healthcare systems and raise diagnostic awareness further support expansion.

This report provides an in depth analysis of various factors that impact the dynamics of Global Short Bowel Syndrome Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers

• Technological advancements
• Increasing healthcare expenditure
• Rising prevalence of short bowel syndrome

• Growing demand for effective treatments: The Global Short Bowel Syndrome (SBS) Therapeutics Market is experiencing substantial growth driven by the increasing demand for effective treatments. Short Bowel Syndrome, a condition characterized by malabsorption due to significant loss of functional small intestine, requires specialized therapeutic interventions to manage the complex nutritional deficiencies and associated complications. The rising prevalence of SBS, driven by factors such as increased survival rates of preterm infants and advancements in surgical procedures, has heightened the need for innovative and effective treatment options. This has spurred significant investments in research and development, leading to the introduction of novel therapies that improve patient outcomes and quality of life.

  One of the critical drivers of this market is the development and approval of advanced pharmacological therapies. Recent years have seen the introduction of GLP-2 analogs like teduglutide, which enhances intestinal absorption and reduces the dependence on parenteral nutrition. These advancements represent a significant shift from traditional management strategies, which primarily focused on dietary modifications and parenteral nutrition. The increasing adoption of such innovative treatments is bolstered by clinical evidence demonstrating their efficacy in promoting intestinal adaptation and improving nutritional absorption, thereby offering a more sustainable and less invasive option for patients with SBS.

  The market growth is supported by favorable regulatory environments and increased awareness among healthcare professionals and patients. Regulatory agencies like the FDA and EMA have granted orphan drug status to several SBS therapies, facilitating faster approval processes and encouraging pharmaceutical companies to invest in this niche market. Public and private healthcare providers are also playing a crucial role by incorporating SBS treatments into reimbursement programs, making these therapies more accessible to a broader patient population. As awareness of SBS and its management continues to grow, the demand for effective therapeutics is expected to rise, driving further innovation and expansion in the global SBS therapeutics market.

Restraints

• Limited awareness
• High treatment costs
• Stringent regulatory requirements

• Side effects of existing therapies: The global short bowel syndrome (SBS) therapeutics market has been evolving rapidly due to advancements in medical treatments and increased understanding of the condition. SBS, a malabsorption disorder resulting from significant resection of the small intestine, poses significant treatment challenges. Therapeutics for SBS aim to enhance nutrient absorption, improve hydration, and minimize complications. Current treatments include parenteral nutrition (PN), enteral nutrition, and various pharmacological agents like teduglutide (Gattex) and somatropin (Zorbtive). Despite these advancements, the market is driven by the need for more effective therapies that offer better patient outcomes and fewer side effects.

  Existing therapies for SBS, while beneficial, come with a range of side effects that can impact patient quality of life. Parenteral nutrition, often essential for patients with severe SBS, carries risks such as catheter-related infections, liver disease, and metabolic bone disease. Long-term dependence on PN can lead to complications like hepatic steatosis, cholestasis, and even liver failure. Pharmacological treatments like teduglutide, a glucagon-like peptide-2 analog, have been shown to reduce PN dependence but are associated with side effects including abdominal pain, nausea, and injection site reactions. Additionally, somatropin, a growth hormone, can cause edema, joint pain, and glucose intolerance, further complicating treatment regimens for SBS patients.

  The ongoing challenge for the SBS therapeutics market is to develop treatments that minimize these adverse effects while maximizing therapeutic benefits. Research is focused on newer agents that can promote intestinal adaptation and function with fewer side effects. For instance, innovative therapies like recombinant human growth hormone and glucagon-like peptide-2 analogs are being optimized to reduce systemic impacts. There is also significant interest in microbiome-based therapies and regenerative medicine approaches, which hold promise for enhancing gut health and functionality. As the market continues to grow, the emphasis remains on balancing efficacy with safety, aiming to improve the overall quality of life for individuals living with SBS.

Opportunities

• Novel drug development
• Emerging markets expansion
• Collaborative research initiatives

• Personalized medicine approaches: The global short bowel syndrome (SBS) therapeutics market is experiencing significant growth due to increasing awareness, improved diagnostic techniques, and advancements in treatment options. SBS is a complex condition that arises from the surgical removal of a significant portion of the small intestine, leading to malabsorption and various nutritional deficiencies. The market is driven by a combination of rising prevalence of gastrointestinal diseases, advancements in medical technologies, and the introduction of novel therapies. Key players in this market are investing heavily in research and development to create more effective treatments, including new pharmacological agents that can enhance intestinal absorption and mitigate the symptoms of SBS.

  Personalized medicine approaches are becoming increasingly prominent in the management of short bowel syndrome. Personalized medicine involves tailoring treatment strategies to the individual characteristics of each patient, including their genetic makeup, disease presentation, and response to previous therapies. In the context of SBS, this approach can lead to more effective management of the condition by optimizing nutritional support, pharmacotherapy, and surgical interventions based on the patient's specific needs. For instance, some patients may benefit more from certain medications that enhance intestinal adaptation, while others might require specialized diets or parenteral nutrition tailored to their unique metabolic requirements.

  The integration of personalized medicine into the SBS therapeutics market is expected to revolutionize patient care by improving outcomes and reducing healthcare costs. By focusing on individualized treatment plans, healthcare providers can minimize trial-and-error approaches, thereby enhancing the quality of life for patients with SBS. Additionally, advancements in genomic and proteomic technologies are enabling the identification of biomarkers that can predict treatment response, further refining the personalized approach. As these technologies continue to evolve, the market for SBS therapeutics is likely to see more targeted and effective treatment modalities, contributing to sustained growth and innovation in this specialized field of medicine.

Key players in Global Short Bowel Syndrome Therapeutics Market include:

• Takeda Pharmaceutical Company Limited
• AbbVie Inc
• Novartis International AG
• Pfizer Inc
• Shire
• Fresenius Kabi AG
• Nestlé Health Science
• Emmaus Life Sciences, Inc
• Zealand Pharma A/S
• Nutrinia Ltd

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis